If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  No Increased Risk of Suicide in Patients With Bipolar Disorder Taking Antiepileptic Drugs CHICAGO -- December 7, 2009 -- Despite government warnings about an increased risk of suicidal thoughts and actions in individuals taking antiepileptic drugs, these medications do not appear to be associated with increased risk of suicide attempts in patients with bipolar disorder, and may have a possible protective effect, according to a report in the December issue of Archives of General Psychiatry. “On Jan. 31, 2008, the Food and Drug Administration issued an alert regarding increased risk of suicidal thoughts and behavior related to use of antiepileptic drugs,” the authors state. “On July 10, 2008, a Food and Drug Administration scientific advisory committee voted that, yes, there was a significant positive association between antiepileptic drugs and suicidality but voted against placing a black box warning on antiepileptic drugs for suicidality.” Individuals with bipolar disorder -- often treated with antiepileptic drugs, such as gabapentin, pregabalin, topiramate, and carbamazepine -- have a higher risk of attempted and completed suicide than the general population. “That makes this a population of interest in detecting the effect on suicide risk of antiepileptic drugs compared with a no-treatment control group,” the authors write. Robert D. Gibbons, PhD, University of Illinois at Chicago, Chicago, Illinois, and colleagues studied a cohort of 47,918 patients with bipolar disorder for whom they had at least 1 year of data before and after diagnosis in a national database of medical claims. A total of 13,385 patients received 1 of 11 antiepileptic drugs and 25,432 received neither antiepileptic medications nor lithium. After treatment, those receiving antiepileptic drugs had similar rates of suicide attempts (13 per 1,000 patients per year) as those taking lithium (18 per 1,000 patients per year) or those who did not receive treatment (13 per 1,000 patients per year). Among those receiving antiepileptic drugs, the rate of suicide attempt was significantly lower after treatment (13 per 1,000 patients per year) than before treatment (72 per 1,000 patients per year). In patients who were not receiving treatment with another antiepileptic, an antidepressant, or an antipsychotic medication, taking any antiepileptic mediation appeared protective against suicide attempts relative to no pharmacologic treatment (3 per 1,000 suicide attempts per patient per year vs 15 per 1,000 per patient per year). “Our analysis also reveals that there is a selection effect, in that the pretreatment suicide attempt rate is five times higher than the rate in untreated patients,” the authors write. “If pretreatment suicide attempt rates reflect the severity of illness, it is the more severely impaired patients who receive treatment with an antiepileptic drug or lithium. Nevertheless, the post-treatment suicide attempt rate is significantly reduced relative to their elevated pretreatment levels to the level found at or below patients not receiving treatment. This finding suggests a possible protective effect of antiepileptic drug treatment on suicidality.” This study was supported by grants from the National Institute of Mental Health and a grant from the Agency for Healthcare Research and Quality.
SOURCE: Archives of General Psychiatry
|
